Notice of Intent to Sole Source: Procurement of CellGenix GMP rh IL-4 Reagent for Cancer Vaccine Clinical Trials
General Information
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Aug 09, 2022 10:54 am EDT
- Original Response Date: Aug 15, 2022 12:00 pm EDT
- Inactive Policy: 15 days after response date
- Original Inactive Date:
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code: 6640 - LABORATORY EQUIPMENT AND SUPPLIES
- NAICS Code:
- 325414 - Biological Product (except Diagnostic) Manufacturing
- Place of Performance: Bethesda , MD 20892USA
Description
PLEASE SEE ATTACHED PDF
The National Cancer Institute (NCI), Center for Cancer Research (CCR), Vaccine Branch (VB) requires CellGenix GMP rh IL-4 reagent for cancer vaccine clinical trials.
The Office of Acquisitions (OA) plans to procure, on a sole source basis, the IL-4 reagent from CellGenix USA (One New Hampshire Ave. Ste. 125 Portsmouth, NH 03801-2907).
The response close date of this notice for this requirement is in accordance with FAR 5.203(b). This acquisition will be processed under FAR Part 12 – Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(1); and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 325414 – Biological Product (except Diagnostic) Manufacturing.
Attachments/Links
Contact Information
Contracting Office Address
- OFFICE OF ACQUISITIONS 31Center Dr. 11A35P
- Bethesda , MD 20892
- USA
Primary Point of Contact
- Lena Lee, Contract Specialist
- lena.lee@nih.gov
Secondary Point of Contact
- Reyes Rodriguez, Contracting Officer
- reyes.rodriguez@nih.gov
History
- Aug 30, 2022 11:55 pm EDTSpecial Notice (Original)